Literature DB >> 27881816

Hypothermia-treated neonates with hypoxic-ischemic encephalopathy: Optimal timing of quantitative ADC measurement to predict disease severity.

Yauk K Lee1, Alex Penn1, Mahesh Patel1, Rajul Pandit1, Dongli Song2, Bo Yoon Ha1.   

Abstract

To determine the optimal time window for MR imaging with quantitative ADC measurement in neonatal HIE after hypothermia treatment, a retrospective review was performed on consecutive hypothermia-treated term neonates with HIE, with an initial and follow-up MR imaging within the first two weeks of life. Three neuroradiologists categorized each set of MR imaging as normal, mild, moderate or severe HIE based on a consensus review of the serial imaging. The lowest ADC values from the white matter, corpus callosum, and basal ganglia/thalamus were measured. The ADC values between mild-moderate and severe HIE were compared using a Student's t-test over a range of different time windows. A total of 33 MR imaging examinations were performed on 16 neonates that included three normal, four mild, five moderate, and four severe HIE. The time window of 3-10 days showed a statistically significant decrease in ADC value in severe HIE compared to mild-moderate HIE in all three locations, respectively: white matter 0.5 ± 0.22 versus 0.83 ± 0.27 ( p value 0.01), corpus callosum 0.69 ± 0.19 versus 0.91 ± 0.17 ( p value 0.01), and basal ganglia/thalamus 0.63 ± 0.16 versus 0.98 ± 0.06 ( p value <0.01). The range of 3-10 days is the optimal time window for MR imaging with quantitative ADC after hypothermia treatment.

Entities:  

Keywords:  ADC; DWI; Hypothermia; MR; encephalopathy; hypoxia; ischemia; measurement; neonate

Mesh:

Year:  2016        PMID: 27881816      PMCID: PMC5564338          DOI: 10.1177/1971400916678229

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  33 in total

1.  Diffusion-weighted magnetic resonance imaging in term perinatal brain injury: a comparison with site of lesion and time from birth.

Authors:  Mary Rutherford; Serena Counsell; Joanna Allsop; James Boardman; Olga Kapellou; David Larkman; Jo Hajnal; David Edwards; Frances Cowan
Journal:  Pediatrics       Date:  2004-10       Impact factor: 7.124

2.  Therapeutic hypothermia for neonatal encephalopathy results in improved microstructure and metabolism in the deep gray nuclei.

Authors:  S L Bonifacio; A Saporta; H C Glass; P Lee; D V Glidden; D M Ferriero; A J Barkovich; D Xu
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-17       Impact factor: 3.825

3.  Patterns of brain injury in term neonatal encephalopathy.

Authors:  Steven P Miller; Vijay Ramaswamy; David Michelson; A James Barkovich; Barbara Holshouser; Nathaniel Wycliffe; David V Glidden; Douglas Deming; J Colin Partridge; Yvonne W Wu; Stephen Ashwal; Donna M Ferriero
Journal:  J Pediatr       Date:  2005-04       Impact factor: 4.406

4.  Acute neonatal morbidity and long-term central nervous system sequelae of perinatal asphyxia in term infants.

Authors:  S Shankaran; E Woldt; T Koepke; M P Bedard; R Nandyal
Journal:  Early Hum Dev       Date:  1991-05       Impact factor: 2.079

5.  Post-hypoxic hypothermia reduces cerebrocortical release of NO and excitotoxins.

Authors:  M Thoresen; S Satas; M Puka-Sundvall; A Whitelaw; A Hallström; E M Løberg; U Ungerstedt; P A Steen; H Hagberg
Journal:  Neuroreport       Date:  1997-10-20       Impact factor: 1.837

6.  Proton spectroscopy and diffusion imaging on the first day of life after perinatal asphyxia: preliminary report.

Authors:  A J Barkovich; K D Westmark; H S Bedi; J C Partridge; D M Ferriero; D B Vigneron
Journal:  AJNR Am J Neuroradiol       Date:  2001-10       Impact factor: 3.825

7.  MR imaging of term infants with hypoxic-ischaemic encephalopathy as a predictor of neurodevelopmental outcome and late MRI appearances.

Authors:  Eilish Twomey; Anne Twomey; Stephanie Ryan; John Murphy; Veronica B Donoghue
Journal:  Pediatr Radiol       Date:  2010-05-29

8.  Prognostic utility of magnetic resonance imaging in neonatal hypoxic-ischemic encephalopathy: substudy of a randomized trial.

Authors:  Jeanie L Y Cheong; Lee Coleman; Rod W Hunt; Katherine J Lee; Lex W Doyle; Terrie E Inder; Susan E Jacobs
Journal:  Arch Pediatr Adolesc Med       Date:  2012-07-01

9.  Brain injury following trial of hypothermia for neonatal hypoxic-ischaemic encephalopathy.

Authors:  Seetha Shankaran; Patrick D Barnes; Susan R Hintz; Abbott R Laptook; Kristin M Zaterka-Baxter; Scott A McDonald; Richard A Ehrenkranz; Michele C Walsh; Jon E Tyson; Edward F Donovan; Ronald N Goldberg; Rebecca Bara; Abhik Das; Neil N Finer; Pablo J Sanchez; Brenda B Poindexter; Krisa P Van Meurs; Waldemar A Carlo; Barbara J Stoll; Shahnaz Duara; Ronnie Guillet; Rosemary D Higgins
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2012-11       Impact factor: 5.747

Review 10.  Magnetic resonance imaging in perinatal brain injury: clinical presentation, lesions and outcome.

Authors:  Mary Rutherford; Latha Srinivasan; Leigh Dyet; Phil Ward; Joanna Allsop; Serena Counsell; Frances Cowan
Journal:  Pediatr Radiol       Date:  2006-05-16
View more
  3 in total

Review 1.  The Applicability of Amide Proton Transfer Imaging in the Nervous System: Focus on Hypoxic-Ischemic Encephalopathy in the Neonate.

Authors:  Yang Zheng; Xiaoming Wang
Journal:  Cell Mol Neurobiol       Date:  2017-09-23       Impact factor: 5.046

2.  Cerebral perfusion changes of the basal ganglia and thalami in full-term neonates with hypoxic-ischaemic encephalopathy: a three-dimensional pseudo continuous arterial spin labelling perfusion magnetic resonance imaging study.

Authors:  Jibin Cao; Yongnan Mu; Xiaohan Xu; Huanhuan Li; Zequn Liu; Meiling Cao; Peng Wang; Wenge Sun; Lingling Cui
Journal:  Pediatr Radiol       Date:  2022-03-31

3.  Application of a 3D pseudocontinuous arterial spin-labeled perfusion MRI scan combined with a postlabeling delay value in the diagnosis of neonatal hypoxic-ischemic encephalopathy.

Authors:  Shilong Tang; Xianfan Liu; Ling He; Bo Liu; Bin Qin; Chuan Feng
Journal:  PLoS One       Date:  2019-07-08       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.